For decades, scientists have known that the longer you stay awake, the stronger the urge to sleep becomes. But the molecular signal that tracks accumulated wakefulness and ultimately flips the switch toward sleep has remained elusive. A study published in Nature Neuroscience by Cao and colleagues identifies that signal: tryptamine, a trace amine produced by the same neurons that keep you alert during the day.
The discovery reveals a previously unknown feedback loop — wake-active neurons gradually release tryptamine as a byproduct of their own activity, and when enough accumulates, it activates a receptor that triggers sleep. The finding opens a direct path to a new category of sleep medications.
A Built-In Sleep Timer
Tryptamine is produced by monoaminergic neurons in the diencephalon and brainstem — the same populations of neurons that release serotonin, norepinephrine, and dopamine to maintain wakefulness. The researchers found that tryptamine is secreted in an activity-dependent manner: the longer these wake-promoting neurons fire, the more tryptamine they release into cerebrospinal fluid.
Crucially, cerebrospinal fluid levels of tryptamine tracked homeostatic sleep pressure in both nocturnal mice and diurnal pigs, and reflected physical activity history independently of light-dark cycles. This means tryptamine doesn't simply follow the circadian clock — it measures how long and how hard the brain has been working.
How Tryptamine Triggers Sleep
Once released, tryptamine binds to G-protein-coupled receptor 139 (GPR139) on neurons in the hypothalamic preoptic area — a brain region long known to promote sleep onset. Activation of GPR139 enhances the excitability of these preoptic neurons, which in turn suppress the wake-promoting circuits that generated the tryptamine in the first place.
The result is an elegant negative feedback loop: wakefulness generates tryptamine, tryptamine activates GPR139, GPR139 activation promotes sleep, and sleep allows tryptamine levels to fall back to baseline.
The researchers confirmed this mechanism was functionally necessary. When GPR139 signaling was disrupted, animals failed to mount a normal homeostatic sleep rebound after sleep deprivation — they had been awake long enough to need recovery sleep, but the molecular signal to initiate it was missing.
A New Class of Sleep Medication
Perhaps the most clinically significant finding is that small-molecule GPR139 agonists — synthetic compounds that activate the same receptor — promoted both sleep duration and sleep quality in animal models. Unlike existing sleep medications, which generally work by broadly suppressing brain activity (benzodiazepines, Z-drugs) or blocking wakefulness signals (orexin antagonists like suvorexant), GPR139 agonists would work by amplifying the brain's own sleep-initiation pathway.
This distinction matters. Current hypnotics are associated with next-day grogginess, dependence, and altered sleep architecture. A drug that enhances the natural homeostatic sleep signal could theoretically produce more physiologically normal sleep — though that hypothesis remains to be tested in humans.
Limitations
The study was conducted in mice and pigs, and the GPR139 agonists tested have not entered human clinical trials. Whether tryptamine-GPR139 signaling operates identically in the human brain, and whether synthetic agonists can selectively promote sleep without off-target effects, will require years of additional research. GPR139 is expressed in multiple brain regions and has been implicated in other functions, including locomotion and anxiety, which could complicate drug development.
What This Means for Patients
The discovery does not change clinical practice today, but it reframes the landscape of sleep drug development. The approximately 50 to 70 million Americans with chronic sleep disorders currently have limited pharmacological options, all of which carry tradeoffs. A drug class that works with the brain's endogenous sleep-pressure system rather than overriding it would represent a fundamentally different approach — one that the tryptamine-GPR139 pathway now makes conceivable.
The study was published in Nature Neuroscience (DOI: 10.1038/s41593-026-02332-x).
